Treatment of relapsed chronic lymphocytic leukemia after venetoclax

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):18-23. doi: 10.1182/hematology.2020000160.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage*
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 13 / genetics*
  • Chromosomes, Human, Pair 17 / genetics
  • Chromosomes, Human, Pair 17 / metabolism
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell* / metabolism
  • Male
  • Recurrence
  • Rituximab / administration & dosage*
  • Smith-Magenis Syndrome* / drug therapy
  • Smith-Magenis Syndrome* / genetics
  • Smith-Magenis Syndrome* / metabolism
  • Smith-Magenis Syndrome* / pathology
  • Sulfonamides / administration & dosage*
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Rituximab
  • venetoclax

Supplementary concepts

  • Chromosome 17 deletion